Erratum: Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab

Frontiers Production Office

DOI: https://doi.org/10.3389/fphar.2022.1092147

IF: 5.6

2022-11-22

Frontiers in Pharmacology

Abstract:[This corrects the article DOI: 10.3389/fphar.2022.973448.].

pharmacology & pharmacy

What problem does this paper attempt to address?

Corrigendum: Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study

Min Yuan,Zhongzheng Zhu,Wei Mao,Hui Wang,Hong Qian,Jianguo Wu,Xianling Guo,Qing Xu

DOI: https://doi.org/10.3389/fonc.2021.796625

IF: 4.7

2022-01-04

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2021.683502.].

oncology
Erratum: Editorial: Angiogenesis and tumor metastasis

Frontiers Production Office

DOI: https://doi.org/10.3389/fonc.2024.1364928

IF: 4.7

2024-01-12

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2022.1129736.].

oncology
Correction To: Early Presence of Anti-Angiogenesis-related Adverse Events As a Potential Biomarker of Antitumor Efficacy in Metastatic Gastric Cancer Patients Treated with Apatinib: a Cohort Study

Xinyang Liu,Shukui Qin,Zhichao Wang,Jianming Xu,Jianping Xiong,Yuxian Bai,Zhehai Wang,Yan Yang,Guoping Sun,Liwei Wang,Leizhen Zheng,Nong Xu,Ying Cheng,Weijian Guo,Hao Yu,Tianshu Liu,Pagona Lagiou,Jin Li

DOI: https://doi.org/10.1186/s13045-017-0545-5

IF: 28.5

2017-01-01

Journal of Hematology & Oncology

Abstract:The original article [1] contains two errors in Table 2
Erratum: Preoperative immunological plasma markers TRAIL, CSF1, and TIE2 predict survival after resection for biliary tract cancer

Frontiers Production Office

DOI: https://doi.org/10.3389/fonc.2023.1281693

2023-09-27

Abstract:[This corrects the article DOI: 10.3389/fonc.2023.1169537.].
Erratum to "Additional biomarkers for pathological complete response in triple negative breast cancer"

DOI: https://doi.org/10.1177/17588359241290373

2024-10-21

Abstract:[This corrects the article DOI: 10.1177/17588359241267148.].
Erratum: Author correction to '3- O-Acetyl-11-keto- β-boswellic acid ameliorated aberrant metabolic landscape and inhibited autophagy in glioblastoma' [Acta Pharm Sin B 10 (2020) 301-312]

Wan Li,Liwen Ren,Xiangjin Zheng,Jinyi Liu,Jinhua Wang,Tengfei Ji,Guanhua Du

DOI: https://doi.org/10.1016/j.apsb.2024.04.025

Abstract:[This corrects the article DOI: 10.1016/j.apsb.2019.12.012.].
Erratum: Clinical insights into nanomedicine and biosafety: advanced therapeutic approaches for common urological cancers

Frontiers Production Office

DOI: https://doi.org/10.3389/fonc.2024.1516456

IF: 4.7

2024-11-06

Frontiers in Oncology

Abstract:This article is an erratum on: Clinical insights into nanomedicine and biosafety: advanced therapeutic approaches for common urological cancers

oncology
Erratum: Jayappa KD, Portell CA, Gordon VL, et al. Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL. Blood Adv. 2017;1(14):933-946

DOI: https://doi.org/10.1182/bloodadvances.2017011148

2017-08-17

Abstract:[This corrects the article DOI: 10.1182/bloodadvances.2016004176.].
Erratum: Author correction to 'VEGFR2-targeted antibody fused with IFNamut regulates the tumor microenvironment of colorectal cancer and exhibits potent anti-tumor and anti-metastasis activity' [Acta Pharm Sin B 11 (2021) 420-433]

Pengzhao Shang,Rui Gao,Yijia Zhu,Xiaorui Zhang,Yang Wang,Minji Guo,Hui Peng,Min Wang,Juan Zhang

DOI: https://doi.org/10.1016/j.apsb.2024.02.014

Abstract:[This corrects the article DOI: 10.1016/j.apsb.2020.09.008.].
Retraction: The efficacy and adverse effects of anlotinib in the treatment of high-grade glioma: a retrospective analysis

Frontiers Editorial Office

DOI: https://doi.org/10.3389/fonc.2024.1383410

IF: 4.7

2024-02-20

Frontiers in Oncology

Abstract:This article is a retraction of: The efficacy and adverse effects of anlotinib in the treatment of high-grade glioma: A retrospective analysis

oncology
Erratum: "Lung cancer in patients with fibrosing interstitial lung diseases: an overview of current knowledge and challenges". Namrata Kewalramani, Carlos Machahua, Venerino Poletti, Jacques Cadranel, Athol U. Wells and Manuela Funke-Chambour. ERJ Open Res 2022; 8: 00115-2022

DOI: https://doi.org/10.1183/23120541.50115-2022

2022-10-03

Abstract:[This corrects the article DOI: 10.1183/23120541.00115-2022.].
Βklotho is Identified As a Target for Theranostics in Non-Small Cell Lung Cancer: Erratum

Lina Fan,Xiyao Li,Ziming Li,Wei Ji,Shun Lü,Weiliang Xia

DOI: https://doi.org/10.7150/thno.86780

IF: 11.6

2023-01-01

Theranostics

Abstract:[This corrects the article DOI: 10.7150/thno.35582.].
Erratum to “Berbamine Suppresses the Progression of Bladder Cancer by Modulating the ROS/NF-κB Axis”

Chenglin Han,Zilong Wang,Shuxiao Chen,Lin Li,Yingkun Xu,Weiting Kang,Chunxiao Wei,Hongbin Ma,Muwen Wang,Xunbo Jin

DOI: https://doi.org/10.1155/2021/9857803

2021-12-14

Oxidative Medicine and Cellular Longevity

Abstract:[This corrects the article DOI: 10.1155/2021/8851763.].

cell biology
Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase: Erratum

Jiang-Kai Dong,Hui-Min Lei,Qian Liang,Ya-Bin Tang,Ye Zhou,Yang Wang,Shengzhe Zhang,Wen-Bin Li,Yunguang Tong,Guanglei Zhuang,Liang Zhang,Hong-Zhuan Chen,Liang Zhu,Ying Shen

DOI: https://doi.org/10.7150/thno.58558

IF: 11.6

2021-01-01

Theranostics

Abstract:[This corrects the article DOI: 10.7150/thno.23177.].

medicine, research & experimental
Erratum: Advances in RIPK1 kinase inhibitors

DOI: https://doi.org/10.3389/fphar.2022.1123234

IF: 5.6

2023-01-09

Frontiers in Pharmacology

Abstract:[This corrects the article DOI: 10.3389/fphar.2022.976435.].

pharmacology & pharmacy
Erratum: Approaching hemophagocytic lymphohistiocytosis

Frontiers Production Office

DOI: https://doi.org/10.3389/fimmu.2024.1369687

IF: 7.3

2024-01-22

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2023.1210041.].

immunology
Erratum: Dual inhibition of PFKFB3 and VEGF normalizes tumor vasculature, reduces lactate production, and improves chemotherapy in glioblastoma: insights from protein expression profiling and MRI: Erratum

Junfeng Zhang,Wei Xue,Kai Xu,Liang Yi,Yu Guo,Tian Xie,Haipeng Tong,Bo Zhou,Shunan Wang,Qing Li,Heng Liu,Xiao Chen,Jingqin Fang,Weiguo Zhang

DOI: https://doi.org/10.7150/thno.92042

IF: 11.6

2023-11-17

Theranostics

Abstract:[This corrects the article DOI: 10.7150/thno.44427.].
Erratum: New insights into the role of macrophages in cancer immunotherapy

Frontiers Production Office

DOI: https://doi.org/10.3389/fimmu.2024.1427337

IF: 7.3

2024-05-17

Frontiers in Immunology

Abstract:This article is an erratum on: New insights into the role of macrophages in cancer immunotherapy

immunology
Erratum: Recombinant Mutated Human TNF in Combination with Chemotherapy for Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Phase III Study.

Xiaowen Ma,Yang Song,Kuo Zhang,Lei Shang,Yuan Gao,Wei Zhang,Xiaochang Xue,Huimin Jia,Jian Geng,Wei Zhou,Yazheng Dang,Enxiao Li,Xinyu Ti,Fulin Fan,Yingqi Zhang,Meng Li

DOI: https://doi.org/10.1038/srep46953

IF: 4.6

2018-01-01

Scientific Reports

Abstract:This corrects the article DOI: 10.1038/srep09918.
Erratum: Predicting the survival probability of functional neuroendocrine tumors treated with peptide receptor radionuclide therapy: Serbian experience

Frontiers Production Office

DOI: https://doi.org/10.3389/fendo.2024.1369692

IF: 6.055

2024-01-22

Frontiers in Endocrinology

Abstract:[This corrects the article DOI: 10.3389/fendo.2023.1270421.].

endocrinology & metabolism

Erratum: Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab

Corrigendum: Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study

Erratum: Editorial: Angiogenesis and tumor metastasis

Correction To: Early Presence of Anti-Angiogenesis-related Adverse Events As a Potential Biomarker of Antitumor Efficacy in Metastatic Gastric Cancer Patients Treated with Apatinib: a Cohort Study

Erratum: Preoperative immunological plasma markers TRAIL, CSF1, and TIE2 predict survival after resection for biliary tract cancer

Erratum to "Additional biomarkers for pathological complete response in triple negative breast cancer"

Erratum: Author correction to '3- O-Acetyl-11-keto- β-boswellic acid ameliorated aberrant metabolic landscape and inhibited autophagy in glioblastoma' [Acta Pharm Sin B 10 (2020) 301-312]

Erratum: Clinical insights into nanomedicine and biosafety: advanced therapeutic approaches for common urological cancers

Erratum: Jayappa KD, Portell CA, Gordon VL, et al. Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL. Blood Adv. 2017;1(14):933-946

Erratum: Author correction to 'VEGFR2-targeted antibody fused with IFNamut regulates the tumor microenvironment of colorectal cancer and exhibits potent anti-tumor and anti-metastasis activity' [Acta Pharm Sin B 11 (2021) 420-433]

Retraction: The efficacy and adverse effects of anlotinib in the treatment of high-grade glioma: a retrospective analysis

Erratum: "Lung cancer in patients with fibrosing interstitial lung diseases: an overview of current knowledge and challenges". Namrata Kewalramani, Carlos Machahua, Venerino Poletti, Jacques Cadranel, Athol U. Wells and Manuela Funke-Chambour. ERJ Open Res 2022; 8: 00115-2022

Βklotho is Identified As a Target for Theranostics in Non-Small Cell Lung Cancer: Erratum

Erratum to “Berbamine Suppresses the Progression of Bladder Cancer by Modulating the ROS/NF-κB Axis”

Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase: Erratum

Erratum: Advances in RIPK1 kinase inhibitors

Erratum: Approaching hemophagocytic lymphohistiocytosis

Erratum: Dual inhibition of PFKFB3 and VEGF normalizes tumor vasculature, reduces lactate production, and improves chemotherapy in glioblastoma: insights from protein expression profiling and MRI: Erratum

Erratum: New insights into the role of macrophages in cancer immunotherapy

Erratum: Recombinant Mutated Human TNF in Combination with Chemotherapy for Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Phase III Study.

Erratum: Predicting the survival probability of functional neuroendocrine tumors treated with peptide receptor radionuclide therapy: Serbian experience